Atypical antipsychotic therapy for treatment of schizophrenia in Hong Kong Chinese patients - A cost analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 45, Issue 5, 2007, Pages 264-270

  Law, W L ^a   Hui, H Y ^a   Young, W M ^a   You, Joyce H S ^b  

^a HOSPITAL AUTHORITY   (Hong Kong)

^b Chinese University of Hong Kong   (Hong Kong)

Author keywords

Amisulpride; Cost analysis; Olanzapine; Quetiapine; Risperidone

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; ARTICLE; CHINESE; COST BENEFIT ANALYSIS; DEMOGRAPHY; DRUG COST; DRUG HYPERSENSITIVITY; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HEALTH CARE COST; HONG KONG; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE REGRESSION; PRESCRIPTION; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; SUBSTANCE ABUSE;

EID: 34248388586     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP45264     Document Type: Article

References (24)

1. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. Pharmacoeconomics. 1998; 13: 575-588.
2. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Soc Psychiatry Psychiatr Epidemiol. 2001; 33: 587-595.
3. Cheng CWR, Chan JCN, Tomlinson B, Woo KS, You JHS. Factors associated with healthcare utilization costs for statin therapy - a pilot study in Hong Kong. Int J Clin Pharmacol Ther. 2006; 44: 484-488.
4. Doering S, Muller E, Kopcke W et al. Predictors of relapse and rehospitalization in schizophrenia and schizoaffective disorder. Schizophr Bull. 1998; 24: 87-98.
5. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull. 1998; 34: 75-81.
6. Fuller MA, Shermock KM, Secic M et al. Service use and costs among VA patients with schizophrenia taking risperidone or olanzapine. Psychiatr Serv. 2002; 53: 855-860.
7. Ginsberg G, Lerner Y, Mark M, Popper M. Prior hospitalization and age as predictors of mental health resource utilization in Israel. Soc Sci Med. 1997; 44: 623-633.
8. Harder S, Thurmann P. Economic aspects of drug therapy in hospitals: an issue for clinical pharmacologists. Int J Clin Pharmacol Ther. 1994; 32: 215-218.
9. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther. 1997; 19: 128-138.
10. Lai MS, Chu CS, Lin SH, Lin MS. Prescribing patterns in primary health care in Taiwan. Int J Clin Pharmacol Ther. 1995; 33: 437-441.
11. Mauskopf JA, David K, Grainger DL, Gibson PJ. Annual health outcomes and treatment costs for schizophrenia populations. J Clin Psychiatry. 1999; 60 (Suppl 19): 14-19.
12. NICE clinical guidelines. Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Website: www.nice.org.uk (assessed in April. 2005).
13. Olfson M, Mechanic D, Bayer C, Hansell S, Walkup J, Weiden PJ. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis. 1999; 187: 721-729.
14. Rascati KL, Johnsrud MT, Crismon ML, Lage M, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia. A comparison of costs among Texas Medicaid recipients. Pharmacoeconomics. 2003; 21: 683-697.
15. Rosenheck R, Cramer J, Allan E et al. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs cooperative study group on clozapine in refractory schizophrenia. Arch Gen Psychiatry. 1999; 56: 565-572.
16. Rosenheck R, Leglie D, Sernyak M. From clinical trials to real-world practice: use of atypical antipsychotic medication nationally in the Department of Veterans Affairs. Med Care. 2001; 39: 302-308.
17. Rupp A, Keith SJ. The costs of schizophrenia. Assessing the burden. Psychiatr Clin North Am. 1993; 16: 413-423.
18. Soholm B, Lublin H. Long-term effectiveness of risperidone and olanzapine in resistant or intolerant schizophrenic patients. A mirror study. Acta Psychiatr Scand. 2003; 107: 344-350.
19. Swofford CD, Scheller-Gilkey G, Miller AH et al. Double jeopardy: schizophrenia and substance abuse. Am J Drug Alcohol Abuse. 2000; 26: 343-353.
20. Viale G, Mechling L, Maislin G, Durkin M, Engelhart L, Lawrence BJ. Impact of risperidone on the use of mental health care resources. Psychiatr Serv. 1997; 48: 1153-1159.
21. Wyatt RJ, Henter I, Leary MC, Taylor F. An economic evaluation of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 1995; 30: 196-205.
22. Yim PHW, Yip PSF, Li RHY, Dunn ELW, Yeung WS, Miao YK. Suicide after discharge from psychiatric inpatient care: a case-control study in Hong Kong. Aust N Z J Psychiatry. 2004; 38: 65-72.
23. You JHS, Lau WH, Lee IY, Yung MY, Ching JY, Chan FKC, Lee KKC. Helicobacter pylori eradication prior to initiation of long-term non-steroidal anti-inflammatory drug therapy in Chinese patients - a cost-effectiveness analysis. Int J Clin Pharmacol Ther. 2006; 44: 149-153.
24. Zullino D, Mayland G, Schmidt LG, Fahndrich F, Greil W, Horvath A et al. Prescribing practices in German and Swiss psychiatric university and in non-university hospitals: national differences. Int J Clin Pharmacol Ther. 2005; 43: 339-349.